Celltrion Pharm "Maintain Coverage for Godeks Capsule... Focus on Marketing and Production"

Celltrion Pharm Godeks Capsule.

[Asia Economy Reporter Lee Gwan-ju] Celltrion Pharm announced on the 6th that its liver tonic 'Godeks Capsule' has been finally recognized as 'eligible for reimbursement' in the Health Insurance Review and Assessment Service (HIRA) reimbursement appropriateness evaluation.

Godeks Capsule was selected as an item for HIRA's reimbursement appropriateness evaluation this year, but in the first reimbursement appropriateness re-evaluation by HIRA in July, it received a judgment of 'not eligible for reimbursement.'

In response, Celltrion Pharm filed an objection and submitted additional explanatory materials, resulting in a final decision to maintain reimbursement in the second evaluation.

Following the results of this reimbursement appropriateness evaluation, Celltrion Pharm plans to focus on marketing and production to expand the use of Godeks Capsule, as uncertainties regarding the product have been resolved.

A Celltrion Pharm official stated, "With the decision to maintain reimbursement for Godeks Capsule in this re-evaluation, uncertainties and market concerns regarding product supply and prescriptions have been completely resolved," adding, "Celltrion Pharm will continue to do its best to contribute to the improvement of public health by supplying high-quality medicines at reasonable prices."

This content was produced with the assistance of AI translation services.